HCID 23498836, Verbindung → HCID 44299385, Verbindung
Reaktionsgleichung
[CH3:1][N:2]1[CH2:7][CH2:6][N:5]([C:8](=[O:22])[CH2:9][CH2:10][C:11]2[C:19]3[CH2:18][CH2:17][CH2:16][CH2:15][C:14]=3[NH:13][C:12]=2[CH:20]=O)[CH2:4][CH2:3]1.[CH2:23]([S:25]([C:28]1[CH:29]=[C:30]2[C:34](=[CH:35][CH:36]=1)[NH:33][C:32](=[O:37])[CH2:31]2)(=[O:27])=[O:26])[CH3:24]>>[CH2:23]([S:25]([C:28]1[CH:29]=[C:30]2[C:34](=[CH:35][CH:36]=1)[NH:33][C:32](=[O:37])/[C:31]/2=[CH:20]\[C:12]1[NH:13][C:14]2[CH2:15][CH2:16][CH2:17][CH2:18][C:19]=2[C:11]=1[CH2:10][CH2:9][C:8]([N:5]1[CH2:6][CH2:7][N:2]([CH3:1])[CH2:3][CH2:4]1)=[O:22])(=[O:26])=[O:27])[CH3:24]Komponenten
3
Versuchsvorschrift
3-[3-(4-Methylpiperazin-1-yl)-3-oxo-propyl]-4,5,6,7-tetrahydro-1H-indole-2-carbaldehyde, prepared as described in Example 4 above, was condensed with 5-ethylsulfonyloxindole (see Example 5) following the same procedure used in Example 1 to provide the desired product (80 mg, 53%).
Quellen und Nachweise
- ORD-Eintrag
- ord-9011a5e62a934292bec65722d284712d
- Quelldatensatz
- uspto-grants-2004_08